Harpreet Singh, MD, former director of the FDA's Division of Oncology 2 and chief medical officer of Precision for Medicine, ...

The FDA has approved the combination of lurbinectedin (Zepzelca) and the immunotherapy atezolizumab (Tecentriq) for first-line maintenance treatment in patients with extensive-stage small cell lung ...

Innovative NBTXR3 shows promise in enhancing radiotherapy for recurrent head and neck cancer, potentially transforming ...

Received folinic acid/fluorouracil/oxaliplatin/bevacizumab in first line with initial partial response; progression after 11 ...

The fast track designation is supported by preclinical evidence of antitumor activity by ADCE-D01 in several STS tumor models ...

Claudine Isaacs, MD: For this patient who's progressed after more than 12 months with an ESR1 mutation and HER2-low disease ...

Harpreet Singh, MD, former director of the FDA's Division of Oncology 2 and chief medical officer of Precision for Medicine, discusses the FDA's draft guidance on the use of overall survival (OS) as ...

Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...

A groundbreaking study reveals the potential of alternative donors in bone marrow transplantation, paving the way for improved patient outcomes and innovative practices.

The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...

The FDA has approved cemiplimab as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma. The US FDA has ...

The TROPION-Breast02 trial is the first to show overall survival benefit in this patient population, indicating a potential ...